Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $21.10

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus rating of “Buy” from the eleven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $21.10.

TRVI has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. B. Riley Financial upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. Morgan Stanley upped their price objective on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Stifel Nicolaus increased their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, Leerink Partners boosted their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its stake in shares of Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Trevi Therapeutics in the fourth quarter valued at about $40,000. Caitong International Asset Management Co. Ltd bought a new position in Trevi Therapeutics in the fourth quarter valued at about $50,000. Strs Ohio acquired a new position in Trevi Therapeutics during the first quarter worth about $52,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in Trevi Therapeutics during the second quarter worth about $56,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Trading Up 1.2%

NASDAQ TRVI opened at $13.08 on Tuesday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -35.35 and a beta of 0.94. The company has a 50 day moving average of $11.25 and a 200-day moving average of $10.65. Trevi Therapeutics has a 1-year low of $4.24 and a 1-year high of $14.39.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.